

31 January 2017 EMA/HMPC/748525/2016 Committee on Herbal Medicinal Products (HMPC)

Overview of comments received on European Union herbal monograph on *Glycine max* (L.) Merr., lecithinum (EMA/HMPC/220599/2016)

Final

<u>Table 1</u>: Organisations and/or individuals that commented on the draft European Union herbal monograph on *Glycine max* (L.) Merr., lecithin as released for public consultation on 27 July 2016 until 31 October 2016.

	Organisations and/or individuals
1	Association of the European Self-Medication Industry (AESGP)



An agency of the European Union

© European Medicines Agency, 2017. Reproduction is authorised provided the source is acknowledged.

Table 2: Discussion of comments

General comments to draft document

Interested party	Comment and Rationale	Outcome
AESGP	AESGP welcomes the above-mentioned European Union herbal monograph which, by providing harmonised assessment criteria for lecithinum ex soya- containing products, should facilitate mutual recognition in Europe.	

Specific comments on text

Section number and heading	Interested party	Comment and Rationale	Outcome
2. Qualitative and quantitative composition	AESGP	 ii) Herbal preparations Please replace soya-bean lecithin (de-oiled, enriched phospholipids from soya bean) by Soya-bean lecithin (de-oiled, phospholipids from soya bean) Justification: As justified in the Draft Assessment report on <i>Glycine max</i> (L.) Merr., lecithin (EMA/HMPC/220598/2016), the therapeutic indication retained in the draft monograph (Traditional herbal medicinal product for the relief of temporary fatigue and sensation of weakness) is supported by a long-lasting use of the active substance 'De-oiled, phospholipids from soya beans'. 	Endorsed

Overview of comments received on European Union herbal monograph on Glycine max (L.) Merr., lecithinum (EMA/HMPC/220599/2016)Overview of comments received on European Union herbal monograph on *Glycine max* (L.) Merr., lecithin (EMA/HMPC/220599/2016) EMA/HMPC/748525/2016

Section number and heading	Interested party	Comment and Rationale	Outcome
		phospholipids from soya beans' are:	
		 mild hypercholesterolemia, 	
		 hepatic problems, both not retained as therapeutic indication in the draft monograph. 	
		As a consequence it is not appropriate to list under section 2	
		the active substance 'De-oiled, enriched phospholipids from	
		soya beans'. The active substance to be listed should read 'De-	
		oiled, phospholipids from soya beans'.	

Overview of comments received on European Union herbal monograph on Glycine max (L.) Merr., lecithinum (EMA/HMPC/220599/2016)Overview of comments received on European Union herbal monograph on *Glycine max* (L.) Merr., lecithin (EMA/HMPC/220599/2016) EMA/HMPC/748525/2016